AbbVie is buying Apogee Therapeutics in a $10.9 billion deal, giving AbbVie access to Apogee’s lead inflammatory disease drug candidate, zumilokibart. The drug is being studied for conditions including atopic dermatitis and asthma. This matters because immunology remains one of the most valuable areas in healthcare, and big pharma still needs new growth as patent cliffs and competition pressure older blockbuster drugs.

Winners

Direct deal beneficiaries

AbbVie is the strategic winner because the deal strengthens its immunology pipeline and adds another possible growth driver beyond Humira, Skyrizi and Rinvoq. Apogee is the direct stock winner because the takeover price validates the value of its inflammatory disease pipeline. This group benefits because investors usually reward pipeline expansion when the asset fits the bu ...